[1]ι̿ƽ
ǥ ɹ漼 ɽ ڵ ϴµ Ǵ ̴. 1989 ǥ 翡 Ϲΰ ε ȯ ü (Digoxin reduction products(DRP), Ȱȭ ü) 36%, 13.7% ̴ ܰ 峻 ϴ ̻ Eggerthella lenta ̿ ü ִٰ ̵ ̻ ȭ 翡 ģٴ ˷ ƴ. case-control study θ̽ Ǵ ƮŬ DPR ҵ Ÿ ̵ 峻E. lenta ҷ (digoxin toxicity) ִٰ ߴ. ϰ ƴ. Ȯϰ ʾҴ ᱹ 2013 ǥ ڵ ſ Ȱȭ cytochrome-encoding operon E. lentaϺ strain鿡 Ȯεư operon ȰȭŰ cardiac glycoside reductase ΰ (cgr1 cgr2) Ѵٰ ߴ. ڵ Ȱȭ microbial biomarkersμ õ 迡 ƹ̳ Ư Ƹ operon Ͽ Ȱ Ű ߴ.
Ÿ̷ 귣 ˷ ƼƮƹ̳ θ ǰ ϹǾǰ νĵǰ 翡 Ⱓ ̷ Դ. 캸. 18~64 شǴ 99 , Һ ü 1000mgƼƮƹ̳ 3ð , 3ð 6ð Һ ü мߴ. ƼƮƹ̳ õ üμ acetaminophen sulfate(S)acetaminophen glucuronide(G) мߴµ ƼƮƹ̳ ص phase 2 2 conjugation process(O-sulfonationglucuronidation) Ǵ ˷. S/G κ ƼƮƹ̳ ̸ Ÿ ִ ô̱ ̾. ڰ S/G پ缺 ٰŵ p-cresol sulfate Ҵ. ̴ Ư 峻 ̻ Ǵ p-cresol ƼƮƹ̳ human cytosolic sulfotransferase (SULT1A1)̶ ȿҿ μO-sulfonation ϱ p-cresol sulfate(p-cresolO-sulfonationü) ƼƮƹ̳ sulfonation Ͽ ƼƮƹ̳ (acetaminophen toxicity) ϱ ̾. ϸ, p-cresol ϴ 峻 ̻ ƼƮƹ̳ Ÿ ִٴ ̴.
Ų ġ ǰ ִ װ ϻ縶̵ ȿ ȯ 2-sulphamoylacetylphenol ȯ ȴ. ó 㿡 ϻ縶̵带 汸 Һ ȯü2-sulphamoylcatylphenol Ұ ƴ. ٽ 峻 ȸŰ ȯü ־. 迬 8 strain ϻ縶̵ ȯ ߰, Clostridium sporogenes ȯ ũ Ÿٰ ߴ. 峻 ̻ ̵ ȭ ϻ縶̵ 翡 ִ ̴.
峻 ⼺ տ Ʈδϴ ü acetamideN-(2-hydroxyethyl)-oxamic acid ǹǷ ̵ Ǵ Ư Clostridium perfringens رտ Ʈδϴ 簡 Ͽ ȿ Ҽ ˷ ̴.
L-DOPAHelicobacter pylori Ȱ ִ ݸ 忰ġḦ Ǵ Ļ 峻 ̻ ȿҵ鿡 ฮ Ȱ 5-amino 5-salicylic acid ȯ Ȱ Ѵ.
ɹٽŸƾ hydroxylation, -oxidation, glutathione conjugation, glucuronidation ġµ 峻 ̻ demethylation, carbon-carbon , , oxidation, dihydroxylation, cyclization ȿ ҵ 2011 ǥƴ.
峻 ƴ ܺο Ե տ ؼ Ȱ ִ. Sphingmonas Ibu-2 5 ȿҿ ̺ acid chain ȿ Ҹ ϴ ִ. ǥ H2 Ƽ 峻 ̻ N-oxide Ȱ ϴ ˷ ִ. Ȯ Ȯε ƴ 峻 ̻ ȭ ȿ ִ ϳ ̴. ˷ chloramphenicol, salicylazosulfapridine, carnitine, sorivudine, irinotecan, nitrazepam ִ.
ݱ ַ 峻 ̻ ȿҿ Ȱ ȭ ̴. ȿҵ Ethoxyresorufin-O-deethylase (EROD), Glutathione S-transferase A 1/2 (GSTA1/2), Glutathione S-transferase A4(GSTA4), Glutathione S-transferase M1 (GSTM1), Epoxide hydroxylase 1 (EPHX1) enzyme, Epoxide hydroxylase 2 (EPHX2) enzyme, Sulfotransferase 1C2 (SULT1C2) enzyme, Sulfotransferase 1B1 (SULT1B1) enzyme, N-acetyltransferase 1 (NAT1) &N-acetyltransferase 2 (NAT2), Glutathione peroxidase 2 (GPX2) enzyme ִ. ̷ 峻 ̻ ȭ reduction, hydrolysis, dihydroxylation, acetylation, deacetylation, proteolysis, deconjugation, deglycosylation , پ Ȱ , ģ. ݱ 30 ̻ 鿡 Ͱ , 峻 ̻ ൿп ̴.
翡 ̼ ϴ 鿡 ȣϴ ˷ ִ. Ʈΰ ϴ. 峻 ̻ Ʈΰ 尣ȯ Ȱ ٽɿ Ѵ. 尣ȯ Ʈΰ decojugation Ʈΰ ǹǷ Ȱ ̰ ȴ. 迬 ϸ 뺯 Ʈΰ ݸ, Һ ߴ. ̼ 쵵 Դ. 峻 ̻ ȭ Ʈΰ 峻 ̴. 峻 ̻ 2-methoxy esterone C17 oxireduction C2 demethylation Ȱ ȯ, ȿ .
NSAIIDs εŸ ȭ ջ ʷϰ, (glycocalyx layer) Ѵ. ̷ surfactant-like particles (SLP) brush border membranes (BBM) glycosylation ȭ 峻 (translocation) ϰ ȯ ִ. ̷ 峻 ȯ ȭ ȭ ̾ 2 پ Ȱ, , ൿ ȭ ұ Ѵ.
Proton pump inhibitor pH ½ 峻 ȣ⼺ ⼺ ʷϰ ظ 뼺 ̵ ִ. , 2 ȯ ̻ ͵ .
ֱ pilot study 峻 ̻ Ÿũθ ൿ ȭ ִ ƴ. Ÿũθ ġ(therapeutic index) 뷮 ſ ߿ Ǵ ϳ̴. ȯ 19 뺯 ü м ̵ 뺯 Faecalibacterium prausnitzii Ÿũθ 뷮 Ÿ. ǰ 峻 ȯ濡 ϴ ַ ˷ ̷ 翡 ִ.